There are many further questions in the story of PSMA-617 besides the issues discussed here, such as the optimal dose of the radiopharmaceutical, optimal frequency of administration, or influence of standard of care therapies on the receptor expression or the radiosensitivity of the tumor when given (just) before or in combination with [177Lu]Lu-PSMA-617. Here, FOLH1 is linked to neoplasm.